| Literature DB >> 33789909 |
Sofia Sterner Isaksson1,2, Margareta Bensow Bacos3, Björn Eliasson4, Eva Thors Adolfsson5, Araz Rawshani4, Ulf Lindblad6, Johan Jendle7, Agneta Berglund3, Marcus Lind4,2, Mette Axelsen3.
Abstract
INTRODUCTION: Evidence on the effects of structured nutrition education is weak in adults with type 1 diabetes mellitus (T1D) with moderately impaired glycemic control. Objective was to compare the effects of different types of nutrition education programs on glycemic control, cardiovascular risk factors, quality of life, diet quality and food choices in T1D. RESEARCH DESIGN AND METHODS: A 12 months randomized controlled study conducted at nine diabetes specialist centers with three parallel arms: (i) a food-based approach (FBA) including foods with low glycemic index or (ii) carbohydrate counting (CC) according to today's standard practice or (iii) individual sessions according to routine care (RC). The primary end point was difference in glycated hemoglobin A1c (HbA1c) between groups at 12 months.Entities:
Keywords: diabetes mellitus; diabetic; diet; diet therapy; education; type 1
Year: 2021 PMID: 33789909 PMCID: PMC8016079 DOI: 10.1136/bmjdrc-2020-001971
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Allocation to education groups, drop-out during 12-month follow-up, and resulting analysis populations. CC, carbohydrate counting; FAS, full analysis set population; FBA, food-based advise; PP, per-protocol population; RC, routine care.
Baseline characteristics of subjects participating in the study
| Variables | All subjects n=159 | FBA group | CC group | RC group | P value |
| Age, years | 48.6 (12.0) | 47.7 (11.5) | 49.1 (11.9) | 48.9 (12.6) | 0.814 |
| Sex | |||||
| Females, n (%) | 92 (57.9) | 27 (52.9) | 31 (58.5) | 34 (61.8) | 0.648 |
| Males, n (%) | 67 (42.1) | 24 (47.1) | 22 (41.5) | 21 (38.2) | |
| Weight, kg | 78.9 (14.0) | 79.7 (14.5) | 77.8 (13.0) | 79.3 (14.7) | 0.246 |
| BMI, kg/m2 | 26.4 (3.5) | 26.2 (3.4) | 26.3 (3.5) | 26.8 (3.8) | 0.606 |
| HbA1c | 8.0 (0.7) | 8.1 (0.7) | 7.9 (0.7) | 8.0 (0.7) | 0.543 |
| HbA1c, mmol/mol | 63.9 (7.9) | 64.8 (9.0) | 63.1 (8.0) | 63.7 (6.7) | 0.543 |
| Total cholesterol, mmol/L | 4.7 (0.9) | 4.8 (1.0) | 4.7 (0.8) | 4.7 (0.9) | 0.752 |
| Total cholesterol, mg/dL | 182.8 (34.8) | 185.6 (38.7) | 182.8 (30.9) | 182.8 (34.8) | 0.752 |
| HDL-cholesterol, mmol/L | 1.7 (0.5) | 1.7 (0.5) | 1.7 (0.5) | 1.6 (0.4) | 0.226 |
| HDL-cholesterol, mg/dL | 65.7 (19.4) | 65.7 (19.4) | 65.7 (19.4) | 61.9 (15.5) | 0.226 |
| LDL-cholesterol, mmol/L | 2.7 (0.7) | 2.9 (0.7) | 2.6 (0.6) | 2.7 (0.8) | 0.121 |
| LDL-cholesterol, mg/dL | 104.4 (27.1) | 112.1 (27.1) | 100.5 (23.2) | 104.4 (30.9) | 0.121 |
| Triglycerides, mmol/L | 1.1 (0.7) | 1.1 (0.6) | 1.0 (0.5) | 1.1 (0.9) | 0.815 |
| Triglycerides, mg/dL | 97.4 (62.0) | 97.4 (53.1) | 88.6 (44.3) | 97.4 (79.7) | 0.815 |
| Systolic blood pressure, mm Hg | 127.4 (13.4) | 128.6 (13.1) | 128.9 (13.7) | 124.7 (13.0) | 0.192 |
| Diastolic blood pressure, mm Hg | 74.6 (9.3) | 74.0 (8.1) | 75.3 (10.1) | 74.3 (9.6) | 0.773 |
| Albumin/creatinine ratio, mg/mmol | 1.8 (5.4) | 2.4 (8.0) | 1.2 (2.7) | 1.7 (4.1) | 0.508 |
| Diabetes duration, years | 22.3 (11.6) | 24.1 (11.2) | 20.8 (11.6) | 22.0 (12.0) | 0.345 |
| Insulin regimen: | |||||
| Injection, n (%) | 94 (59.1) | 30 (58,8) | 33 (62.3) | 31 (56.4) | 0.822 |
| Pump, n (%) | 65 (40.9) | 21 (41.2) | 20 (37.7) | 24 (43.6) | |
| Insulin dose, | 0.6 (0.2) | 0.5 (0.2) | 0.6 (0.2) | 0.6 (0.2) | 0.115 |
| Lipid lowering medication, n (%) | 78 (49.1) | 18 (35.3) | 30 (56.6) | 30 (54.5) | 0.057 |
| Antihypertensive medication, n (%) | 9 (5.7) | 4 (7.8) | 4 (7.5) | 1 (1.8) | 0.312 |
| Smoking, n (%) | 13 (8.2) | 5 (9.8) | 6 (11.3) | 2 (3.6) | 0.303 |
| Snuff, n (%) | 19 (11.9) | 4 (7.8) | 11 (20.8) | 4 (7.3) | 0.053 |
| Other nicotine products, n (%) | 3 (1.9) | 1 (2.3) | 2 (4.1) | 0 (0.0) | 0.380 |
Data shown as means (SD) unless otherwise stated.
BMI, body mass index; CC, carbohydrate counting; FBA, food-based advice; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; RC, routine care.
Clinical variables, differences between the groups after 12 months in the full analysis set
| FBA versus RC | CC versus RC | FBA versus CC | |
| HbA1c | 0.0 (0.1) p=0.792 | −0.1 (0.1) p=0.522 | 0.0 (0.0) p=0.754 |
| HbA1c, mmol/mol | −0.4 (1.3) | −0.8 (1.2) | 0.4 (0.3) |
| Total cholesterol, mmol/L | 0.09 (0.06) p=0.131 | 0.05 (0.06) p=0.376 | 0.01 (0.06) p=0.846 |
| HDL cholesterol, mmol/L | −0.01 (0.02) p=0.658 | 0.00 (0.02) p=0.962 | −0.01 (0.02) p=0.547 |
| LDL cholesterol, mmol/L | 0.04 (0.04) p=0284 | 0.07 (0.05) p=0.159 | −0.04 (0.05) p=0.400 |
| Non-HDL cholesterol, mmol/L | 0.08 (0.05) p=0.107 | 0.05 (0.05) p=0.328 | 0.02 (0.05) p=0.610 |
| Triglycerides, mmol/L | −0.03 (0.04) p=0.418 | −0.08 (0.04) p=0.054 | 0.05 (0.04) p=0.194 |
| Systolic blood pressure, mm Hg | −0.42 (1.36) p=0.756 | −0.14 (1.24) p=0.913 | 0.12 (1.34) p=0.928 |
| Diastolic blood pressure. mm Hg | 0.12 (0.86) p=0.887 | −0.14 (0.84) p=0.867 | 0.12 (0.88) p=0.888 |
| Body weight, kg | −0.23 (0.5) p=0.680 | −0.22 (0.60) p=0.713 | 0.05 (0.56) p=0.935 |
| hs-CRP, mg/L | 0.19 (0.35) p=0.586 | 0.35 (0.32) p=0.278 | −0.13 (0.39) p=0.735 |
| Insulin dose, | 0.03 (0.02) p=0.079 | 0.01 (0.02) p=0.625 n=44 vs 42 | 0.03 (0.02) p=0.161 |
| Hypoglycemia | 0.39 (0.06) p=0.000 | 0.05 (0.07) p=0.437 | 0.35 (0.06) p=<0.000 |
| Albumin/Creatinine ratio, mg/mmol | −0.73 (0.76) p=0.339 | −0.00 (0.78) p=0.995 | −0.32 (0.82) p=0.699 |
Data shown as means (SD) unless otherwise stated. All analyses were adjusted for baseline values. The analysis of lipids and blood pressure does not include data from subjects who changed the dose or type of cholesterol/hypertension-lowering medication during the study period.
*Mean (SD) HbA1c at 12 months.
CC, carbohydrate counting; FBA, food-based advice; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; RC, routine care.
Figure 2Glycated hemoglobin A1c (HbA1c) before and after different types of nutrition education in type 1 diabetes. (A) Full analysis set population, (B) per-protocol population. Data presented as means and 95% CI. CC, carbohydrate counting; FBA, food-based advise; RC, routine care.
Baseline data and differences in dietary intake between groups at baseline and after 12 months in the full analysis set
| Baseline | Month 12 | |||||
| FBA | CC | RC | FBA | CC | RC | |
| Energy | 1636 | 1513* | 1821* | 0 | −148 | −94 |
| Carbohydrates | 167† | 177* | 202†* | 0 | −14 | −15 |
| Protein | 71 | 67* | 80* | 0 | −4 | −4 |
| Fat | 65 | 55* | 64* | 0‡ | −5‡ | −3 |
| SFA | 25 | 21 | 24 | 0 | –2 | −2 |
| MUFA | 24‡ | 20‡* | 24* | 0‡† | −2‡ | −1† |
| PUFA | 11 | 10 | 12 | 2‡† | 0‡ | −1† |
| n-3 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 |
| Sucrose | 26 | 27 | 30 | 0† | 0 | −2† |
| Fiber | 21† | 19 | 23† | 0‡ | −2‡ | 0 |
| Wholegrain | 49 | 54 | 65 | 0 | −5 | 8 |
| Legumes | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 |
| Nuts, seeds and almond | 0.3 | 0.5* | 0.1* | 0.2‡† | 0.0 | 0.0 |
| Vegetables and root vegetables | 2.1 | 1.8 | 2.0 | 1.8 | 0.0 | 0.0 |
| Fruit and berries (portions/day) | 1.1 | 1.3 | 1.0 | 0.1 | 0.0 | 0.0 |
| Fish | 0.4 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 |
| Wholegrain products (portions/day) | 2.0 | 1.5 | 2.0 | −1.8 | 0.0 | 0.0 |
Baseline data and differences in dietary intake between groups in FAS analysis expressed in medians and quartiles 1 and 3 at baseline and after 12 months.
*CC versus RC p≤0.05.
†FBA versus RC p<0.05.
‡FBA versus CC p<0.05.
CC, carbohydrate counting; FAS, full analysis set; FBA, food-based advice; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; RC, routine care; SFA, saturated fatty acid.